Columbia, MO, United States of America

Gary Clark

This inventor holds 3 USPTO granted patents. Top assignee: University of Missouri. Active years: 2015-2021.


% Patents Active = 66.7

Average Co-Inventor Count = 1.5

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2015-2021

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Gary Clark: Innovator in Cancer Therapy and Fertility Testing

Introduction

Gary Clark is an accomplished inventor based in Columbia, MO (US). He has made significant contributions to the fields of cancer treatment and reproductive health. With a total of 3 patents, his work focuses on innovative therapeutic approaches and diagnostic systems.

Latest Patents

One of Gary's latest patents is a cancer immune-based therapy. This novel therapeutic vaccine approach aims to trigger a therapeutic antitumor response by selectively eliminating carbohydrate sequences from tumor cells, while preserving tumor-associated protein epitopes. Another significant invention is a system for evaluating the binding of mammalian sperm. This apparatus provides a specific sperm-binding test that mimics the natural binding of sperm to an egg, utilizing surface-modified beads with compounds associated with mammalian zona-pellucida glycoproteins.

Career Highlights

Gary Clark is affiliated with the University of Missouri, where he continues to advance his research and innovations. His work has the potential to impact both cancer treatment and fertility diagnostics significantly.

Collaborations

Some of Gary's notable coworkers include Peter Sutovsky and Breton F Barrier. Their collaborative efforts contribute to the advancement of research in their respective fields.

Conclusion

Gary Clark's innovative work in cancer therapy and fertility testing showcases his dedication to improving health outcomes through scientific advancements. His contributions are paving the way for future developments in these critical areas.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…